OPTN - OptiNose, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.47
+0.24 (+2.92%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close8.23
Open8.28
Bid0.00 x 1300
Ask0.00 x 900
Day's Range8.09 - 8.54
52 Week Range4.44 - 11.66
Volume264,491
Avg. Volume279,401
Market Cap352.197M
Beta (3Y Monthly)0.75
PE Ratio (TTM)N/A
EPS (TTM)-2.70
Earnings DateNov 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.20
  • GlobeNewswire

    Optinose to Present at the Piper Jaffray 31st Annual Healthcare Conference

    YARDLEY, Pa., Nov. 26, 2019 -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today.

  • GlobeNewswire

    Optinose Announces Pricing of Public Offering of Common Stock

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $9.75 per share, before underwriting discounts. The offering consists of 4,250,000 shares being sold by Optinose and 1,250,000 shares being sold by certain selling stockholders, resulting in aggregate net proceeds of approximately $39.0 million to Optinose and approximately $11.5 million to the selling stockholders, after deducting underwriting discounts and before offering expenses. In addition, Optinose and the selling stockholders have granted the underwriters an option for a period of 30 days to purchase up to an additional 825,000 shares at the public offering price, less the underwriting discount.

  • GlobeNewswire

    Optinose Announces Proposed Public Offering of Common Stock

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it and certain selling stockholders intend to offer and sell shares of its common stock in an underwritten public offering. In addition, Optinose is expected to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the total number of shares to be offered at the public offering price, less the underwriting discount. Optinose intends to use the net proceeds of the offering for working capital and general corporate purposes.

  • How health startup Optinose engineered a 300%+ spike in growth
    Yahoo Finance

    How health startup Optinose engineered a 300%+ spike in growth

    Optinose is a $400 million market cap company that's hoping to be a leader in the ears, nose and throat (ENT) space.

  • GlobeNewswire

    Optinose Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

    XHANCE net revenue grew 30% to $8.7 million from second to third quarter 2019 XHANCE prescriptions increased 27% from second to third quarter 2019 Company expects.

  • Hedge Funds Have Never Been More Bullish On OptiNose, Inc. (OPTN)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On OptiNose, Inc. (OPTN)

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

  • Earnings Preview: OptiNose (OPTN) Q3 Earnings Expected to Decline
    Zacks

    Earnings Preview: OptiNose (OPTN) Q3 Earnings Expected to Decline

    OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Optinose to Report Third Quarter 2019 Financial Results and Corporate Updates on November 12, 2019

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the third quarter 2019, after market close on Tuesday, November 12, 2019. Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com.

  • GlobeNewswire

    Optinose Appoints Michael Richardson to New Position of Vice President, Business Development

    YARDLEY, Pa., Oct. 04, 2019 (GLOBE NEWSWIRE) --  Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported the creation of a new role of Vice President, Business Development and appointment of Michael Richardson into the new position. In this role, Michael will be responsible for identifying, evaluating, and executing on business development opportunities that support the overall corporate strategy.

  • GlobeNewswire

    Optinose to Present at the 2019 Cantor Global Healthcare Conference

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the 2019 Cantor Global Healthcare Conference on October 2, 2019, at 11:15 a.m. ET. Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists.

  • PR Newswire

    Currax™ Pharmaceuticals LLC Announces First Acquisition: Acquires North American Rights to ONZETRA® Xsail®

    Currax's first acquisition comes fewer than five months after the company's founding in April of 2019 The acquisition of ONZETRA® Xsail® bolsters Currax's Branded products portfolio MORRISTOWN, N.J. , ...

  • GlobeNewswire

    OptiNose Announces License Agreement Related to ONZETRA XSAIL

    OptiNose, Inc. (Optinose) (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the signing of an agreement between its Norway-based subsidiary OptiNose AS and Currax Pharmaceuticals LLC (Currax) which grants Currax the exclusive rights to certain Optinose intellectual property for the purpose of marketing ONZETRA® XSAIL® (sumatriptan nasal powder) in the United States, Canada, and Mexico. Under the terms of the License Agreement, Currax is required to pay a $4.48 million upfront payment, of which $750,000 shall be held in escrow for a limited period to cover certain indemnification obligations.

  • GlobeNewswire

    Optinose Announces Departure of Chief Commercial Officer

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the departure of its Chief Commercial Officer, Tom Gibbs. Mr. Gibbs will be leaving the Company next week to assume a senior general management role at a major multinational pharmaceutical company. Senior members of the Optinose commercial leadership, including Vice Presidents of sales, marketing, and market access, will report directly to Optinose President and Chief Operating Officer Ramy Mahmoud on an interim basis as the Company initiates a search for a Chief Commercial Officer.

  • GlobeNewswire

    Optinose Announces $150 Million Debt Financing from Pharmakon

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported that it has entered into a note purchase agreement for up to $150 million of senior secured notes with funds managed by Pharmakon Advisors, LP (“Pharmakon”), the investment manager of the BioPharma Credit funds. “The capital available under this facility has the potential to meaningfully extend our cash runway, and Pharmakon’s reputation of forming successful, long-term, relationships with growth-stage companies such as Optinose makes them a great financial partner for us,” commented Chief Financial Officer Keith Goldan.

  • Is OptiNose (NASDAQ:OPTN) Using Debt In A Risky Way?
    Simply Wall St.

    Is OptiNose (NASDAQ:OPTN) Using Debt In A Risky Way?

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

  • Benzinga

    OptiNose's Q2 Results Reflect Strong Underlying Trends, RBC Says

    OptiNose Inc’s (NASDAQ: OPTN ) XHANCE nasal spray continued to exhibit encouraging trends in the second quarter, suggesting that the company's launch is progressing on track, according to RBC Capital Markets. ...

  • OptiNose, Inc. (OPTN) Q2 2019 Earnings Call Transcript
    Motley Fool

    OptiNose, Inc. (OPTN) Q2 2019 Earnings Call Transcript

    OPTN earnings call for the period ending June 30, 2019.

  • OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
    Zacks

    OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates

    OptiNose (OPTN) delivered earnings and revenue surprises of 12.00% and -13.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Optinose Reports Second Quarter 2019 Financial Results and Recent Operational Highlights

    XHANCE net revenue grew 68% to $6.7 million from first to second quarter 2019 XHANCE prescriptions increased 51% from first to second quarter 2019 Company expects XHANCE net.

  • ACCESSWIRE

    OptiNose, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 12, 2019 / OptiNose, Inc. (NASDAQ: OPTN) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 12, 2019 at 4:30 PM Eastern ...

  • Analysts Estimate OptiNose (OPTN) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate OptiNose (OPTN) to Report a Decline in Earnings: What to Look Out for

    OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Optinose to Report Second Quarter 2019 Financial Results and Corporate Updates on August 12, 2019

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the second quarter 2019, after market close on Monday, August 12, 2019. Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com.

  • Those Who Purchased OptiNose (NASDAQ:OPTN) Shares A Year Ago Have A 73% Loss To Show For It
    Simply Wall St.

    Those Who Purchased OptiNose (NASDAQ:OPTN) Shares A Year Ago Have A 73% Loss To Show For It

    OptiNose, Inc. (NASDAQ:OPTN) shareholders should be happy to see the share price up 14% in the last month. But that...

  • GlobeNewswire

    Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the 2019 BMO Capital Markets Prescriptions for Success Healthcare Conference on June 25, 2019, at 9:40 a.m. ET. Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists.